Christina C. Dahm

Soluble Receptor for Advanced Glycation End-products (sRAGE) and colorectal cancer risk: a case-control study nested within a European prospective cohort

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Soluble Receptor for Advanced Glycation End-products (sRAGE) and colorectal cancer risk : a case-control study nested within a European prospective cohort. / Aglago, Elom Kouassivi; Rinaldi, Sabina; Freisling, Heinz; Jiao, Li; Hughes, David J; Fedirko, Veronika; Schalkwijk, Casper G; Weiderpass, Elisabete; Dahm, Christina C; Overvad, Kim; Eriksen, Anne Kirstine; Kyrø, Cecilie; Boutron-Ruault, Marie-Christine; Rothwell, Joseph A; Severi, Gianluca; Katzke, Verena; Kühn, Tilman; Schulze, Matthias B; Aleksandrova, Krasimira; Masala, Giovanna; Krogh, Vittorio; Panico, Salvatore; Tumino, Rosario; Naccarati, Alessio; Bueno-de-Mesquita, Bas; van Gils, Carla H; Sandanger, Torkjel M; Gram, Inger T; Skeie, Guri; Quirós, J Ramón; Jakszyn, Paula; Sánchez, Maria-Jose; Amiano, Pilar; Huerta, José María; Ardanaz, Eva; Johansson, Ingegerd; Harlid, Sophia; Perez-Cornago, Aurora; Mayén, Ana-Lucia; Cordova, Reynalda; Gunter, Marc J; Vineis, Paolo; Cross, Amanda J; Riboli, Elio; Jenab, Mazda.

In: Cancer Epidemiology, Biomarkers & Prevention, Vol. 30, No. 1, 01.2021, p. 182-192.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Aglago, EK, Rinaldi, S, Freisling, H, Jiao, L, Hughes, DJ, Fedirko, V, Schalkwijk, CG, Weiderpass, E, Dahm, CC, Overvad, K, Eriksen, AK, Kyrø, C, Boutron-Ruault, M-C, Rothwell, JA, Severi, G, Katzke, V, Kühn, T, Schulze, MB, Aleksandrova, K, Masala, G, Krogh, V, Panico, S, Tumino, R, Naccarati, A, Bueno-de-Mesquita, B, van Gils, CH, Sandanger, TM, Gram, IT, Skeie, G, Quirós, JR, Jakszyn, P, Sánchez, M-J, Amiano, P, Huerta, JM, Ardanaz, E, Johansson, I, Harlid, S, Perez-Cornago, A, Mayén, A-L, Cordova, R, Gunter, MJ, Vineis, P, Cross, AJ, Riboli, E & Jenab, M 2021, 'Soluble Receptor for Advanced Glycation End-products (sRAGE) and colorectal cancer risk: a case-control study nested within a European prospective cohort', Cancer Epidemiology, Biomarkers & Prevention, vol. 30, no. 1, pp. 182-192. https://doi.org/10.1158/1055-9965.EPI-20-0855

APA

Aglago, E. K., Rinaldi, S., Freisling, H., Jiao, L., Hughes, D. J., Fedirko, V., Schalkwijk, C. G., Weiderpass, E., Dahm, C. C., Overvad, K., Eriksen, A. K., Kyrø, C., Boutron-Ruault, M-C., Rothwell, J. A., Severi, G., Katzke, V., Kühn, T., Schulze, M. B., Aleksandrova, K., ... Jenab, M. (2021). Soluble Receptor for Advanced Glycation End-products (sRAGE) and colorectal cancer risk: a case-control study nested within a European prospective cohort. Cancer Epidemiology, Biomarkers & Prevention, 30(1), 182-192. https://doi.org/10.1158/1055-9965.EPI-20-0855

CBE

Aglago EK, Rinaldi S, Freisling H, Jiao L, Hughes DJ, Fedirko V, Schalkwijk CG, Weiderpass E, Dahm CC, Overvad K, Eriksen AK, Kyrø C, Boutron-Ruault M-C, Rothwell JA, Severi G, Katzke V, Kühn T, Schulze MB, Aleksandrova K, Masala G, Krogh V, Panico S, Tumino R, Naccarati A, Bueno-de-Mesquita B, van Gils CH, Sandanger TM, Gram IT, Skeie G, Quirós JR, Jakszyn P, Sánchez M-J, Amiano P, Huerta JM, Ardanaz E, Johansson I, Harlid S, Perez-Cornago A, Mayén A-L, Cordova R, Gunter MJ, Vineis P, Cross AJ, Riboli E, Jenab M. 2021. Soluble Receptor for Advanced Glycation End-products (sRAGE) and colorectal cancer risk: a case-control study nested within a European prospective cohort. Cancer Epidemiology, Biomarkers & Prevention. 30(1):182-192. https://doi.org/10.1158/1055-9965.EPI-20-0855

MLA

Vancouver

Aglago EK, Rinaldi S, Freisling H, Jiao L, Hughes DJ, Fedirko V et al. Soluble Receptor for Advanced Glycation End-products (sRAGE) and colorectal cancer risk: a case-control study nested within a European prospective cohort. Cancer Epidemiology, Biomarkers & Prevention. 2021 Jan;30(1):182-192. https://doi.org/10.1158/1055-9965.EPI-20-0855

Author

Aglago, Elom Kouassivi ; Rinaldi, Sabina ; Freisling, Heinz ; Jiao, Li ; Hughes, David J ; Fedirko, Veronika ; Schalkwijk, Casper G ; Weiderpass, Elisabete ; Dahm, Christina C ; Overvad, Kim ; Eriksen, Anne Kirstine ; Kyrø, Cecilie ; Boutron-Ruault, Marie-Christine ; Rothwell, Joseph A ; Severi, Gianluca ; Katzke, Verena ; Kühn, Tilman ; Schulze, Matthias B ; Aleksandrova, Krasimira ; Masala, Giovanna ; Krogh, Vittorio ; Panico, Salvatore ; Tumino, Rosario ; Naccarati, Alessio ; Bueno-de-Mesquita, Bas ; van Gils, Carla H ; Sandanger, Torkjel M ; Gram, Inger T ; Skeie, Guri ; Quirós, J Ramón ; Jakszyn, Paula ; Sánchez, Maria-Jose ; Amiano, Pilar ; Huerta, José María ; Ardanaz, Eva ; Johansson, Ingegerd ; Harlid, Sophia ; Perez-Cornago, Aurora ; Mayén, Ana-Lucia ; Cordova, Reynalda ; Gunter, Marc J ; Vineis, Paolo ; Cross, Amanda J ; Riboli, Elio ; Jenab, Mazda. / Soluble Receptor for Advanced Glycation End-products (sRAGE) and colorectal cancer risk : a case-control study nested within a European prospective cohort. In: Cancer Epidemiology, Biomarkers & Prevention. 2021 ; Vol. 30, No. 1. pp. 182-192.

Bibtex

@article{2f826a129ac54b7b93c8963919280e94,
title = "Soluble Receptor for Advanced Glycation End-products (sRAGE) and colorectal cancer risk: a case-control study nested within a European prospective cohort",
abstract = "BACKGROUND: Overexpression of the Receptor for Advanced Glycation End-product (RAGE) has been associated with chronic inflammation, which in turn has been associated with increased colorectal cancer (CRC) risk. Soluble RAGE (sRAGE) competes with RAGE to bind its ligands, thus potentially preventing RAGE-induced inflammation.METHODS: To investigate whether sRAGE and related genetic variants are associated with CRC risk, we conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC). Plasma sRAGE concentrations were measured by ELISA in 1,361 CRC matched case-control sets. Twenty-four single nucleotide polymorphisms (SNPs) encoded in the genes associated with sRAGE concentrations were available for 1,985 CRC cases and 2,220 controls. Multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed using conditional and unconditional logistic regression for CRC risk and circulating sRAGE and SNPs, respectively.RESULTS: Higher sRAGE concentrations were inversely associated with CRC (ORQ5vs.Q1=0.77, 95%CI=0.59-1.00). Sex-specific analyses revealed that the observed inverse risk association was restricted to men (ORQ5vs.Q1=0.63, 95%CI=0.42-0.94) whereas no association was observed in women (ORQ5vs.Q1=1.00, 95%CI=0.68-1.48, Pheterogeneity for sex=0.006). Participants carrying minor allele of rs653765 (promoter region of ADAM10) had lower CRC risk (C vs. T, OR=0.90; 95%CI=0.82-0.99).CONCLUSIONS: Pre-diagnostic sRAGE concentrations were inversely associated with CRC risk in men but not in women. A SNP located within ADAM10 gene pertaining to RAGE shedding, was associated with CRC risk.IMPACT: Further studies are needed to confirm our observed sex difference in the association and better explore the potential involvement of genetic variants of sRAGE in CRC development.",
author = "Aglago, {Elom Kouassivi} and Sabina Rinaldi and Heinz Freisling and Li Jiao and Hughes, {David J} and Veronika Fedirko and Schalkwijk, {Casper G} and Elisabete Weiderpass and Dahm, {Christina C} and Kim Overvad and Eriksen, {Anne Kirstine} and Cecilie Kyr{\o} and Marie-Christine Boutron-Ruault and Rothwell, {Joseph A} and Gianluca Severi and Verena Katzke and Tilman K{\"u}hn and Schulze, {Matthias B} and Krasimira Aleksandrova and Giovanna Masala and Vittorio Krogh and Salvatore Panico and Rosario Tumino and Alessio Naccarati and Bas Bueno-de-Mesquita and {van Gils}, {Carla H} and Sandanger, {Torkjel M} and Gram, {Inger T} and Guri Skeie and Quir{\'o}s, {J Ram{\'o}n} and Paula Jakszyn and Maria-Jose S{\'a}nchez and Pilar Amiano and Huerta, {Jos{\'e} Mar{\'i}a} and Eva Ardanaz and Ingegerd Johansson and Sophia Harlid and Aurora Perez-Cornago and Ana-Lucia May{\'e}n and Reynalda Cordova and Gunter, {Marc J} and Paolo Vineis and Cross, {Amanda J} and Elio Riboli and Mazda Jenab",
note = "Copyright {\textcopyright}2020, American Association for Cancer Research.",
year = "2021",
month = jan,
doi = "10.1158/1055-9965.EPI-20-0855",
language = "English",
volume = "30",
pages = "182--192",
journal = "Cancer Epidemiology, Biomarkers & Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research (A A C R)",
number = "1",

}

RIS

TY - JOUR

T1 - Soluble Receptor for Advanced Glycation End-products (sRAGE) and colorectal cancer risk

T2 - a case-control study nested within a European prospective cohort

AU - Aglago, Elom Kouassivi

AU - Rinaldi, Sabina

AU - Freisling, Heinz

AU - Jiao, Li

AU - Hughes, David J

AU - Fedirko, Veronika

AU - Schalkwijk, Casper G

AU - Weiderpass, Elisabete

AU - Dahm, Christina C

AU - Overvad, Kim

AU - Eriksen, Anne Kirstine

AU - Kyrø, Cecilie

AU - Boutron-Ruault, Marie-Christine

AU - Rothwell, Joseph A

AU - Severi, Gianluca

AU - Katzke, Verena

AU - Kühn, Tilman

AU - Schulze, Matthias B

AU - Aleksandrova, Krasimira

AU - Masala, Giovanna

AU - Krogh, Vittorio

AU - Panico, Salvatore

AU - Tumino, Rosario

AU - Naccarati, Alessio

AU - Bueno-de-Mesquita, Bas

AU - van Gils, Carla H

AU - Sandanger, Torkjel M

AU - Gram, Inger T

AU - Skeie, Guri

AU - Quirós, J Ramón

AU - Jakszyn, Paula

AU - Sánchez, Maria-Jose

AU - Amiano, Pilar

AU - Huerta, José María

AU - Ardanaz, Eva

AU - Johansson, Ingegerd

AU - Harlid, Sophia

AU - Perez-Cornago, Aurora

AU - Mayén, Ana-Lucia

AU - Cordova, Reynalda

AU - Gunter, Marc J

AU - Vineis, Paolo

AU - Cross, Amanda J

AU - Riboli, Elio

AU - Jenab, Mazda

N1 - Copyright ©2020, American Association for Cancer Research.

PY - 2021/1

Y1 - 2021/1

N2 - BACKGROUND: Overexpression of the Receptor for Advanced Glycation End-product (RAGE) has been associated with chronic inflammation, which in turn has been associated with increased colorectal cancer (CRC) risk. Soluble RAGE (sRAGE) competes with RAGE to bind its ligands, thus potentially preventing RAGE-induced inflammation.METHODS: To investigate whether sRAGE and related genetic variants are associated with CRC risk, we conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC). Plasma sRAGE concentrations were measured by ELISA in 1,361 CRC matched case-control sets. Twenty-four single nucleotide polymorphisms (SNPs) encoded in the genes associated with sRAGE concentrations were available for 1,985 CRC cases and 2,220 controls. Multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed using conditional and unconditional logistic regression for CRC risk and circulating sRAGE and SNPs, respectively.RESULTS: Higher sRAGE concentrations were inversely associated with CRC (ORQ5vs.Q1=0.77, 95%CI=0.59-1.00). Sex-specific analyses revealed that the observed inverse risk association was restricted to men (ORQ5vs.Q1=0.63, 95%CI=0.42-0.94) whereas no association was observed in women (ORQ5vs.Q1=1.00, 95%CI=0.68-1.48, Pheterogeneity for sex=0.006). Participants carrying minor allele of rs653765 (promoter region of ADAM10) had lower CRC risk (C vs. T, OR=0.90; 95%CI=0.82-0.99).CONCLUSIONS: Pre-diagnostic sRAGE concentrations were inversely associated with CRC risk in men but not in women. A SNP located within ADAM10 gene pertaining to RAGE shedding, was associated with CRC risk.IMPACT: Further studies are needed to confirm our observed sex difference in the association and better explore the potential involvement of genetic variants of sRAGE in CRC development.

AB - BACKGROUND: Overexpression of the Receptor for Advanced Glycation End-product (RAGE) has been associated with chronic inflammation, which in turn has been associated with increased colorectal cancer (CRC) risk. Soluble RAGE (sRAGE) competes with RAGE to bind its ligands, thus potentially preventing RAGE-induced inflammation.METHODS: To investigate whether sRAGE and related genetic variants are associated with CRC risk, we conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC). Plasma sRAGE concentrations were measured by ELISA in 1,361 CRC matched case-control sets. Twenty-four single nucleotide polymorphisms (SNPs) encoded in the genes associated with sRAGE concentrations were available for 1,985 CRC cases and 2,220 controls. Multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed using conditional and unconditional logistic regression for CRC risk and circulating sRAGE and SNPs, respectively.RESULTS: Higher sRAGE concentrations were inversely associated with CRC (ORQ5vs.Q1=0.77, 95%CI=0.59-1.00). Sex-specific analyses revealed that the observed inverse risk association was restricted to men (ORQ5vs.Q1=0.63, 95%CI=0.42-0.94) whereas no association was observed in women (ORQ5vs.Q1=1.00, 95%CI=0.68-1.48, Pheterogeneity for sex=0.006). Participants carrying minor allele of rs653765 (promoter region of ADAM10) had lower CRC risk (C vs. T, OR=0.90; 95%CI=0.82-0.99).CONCLUSIONS: Pre-diagnostic sRAGE concentrations were inversely associated with CRC risk in men but not in women. A SNP located within ADAM10 gene pertaining to RAGE shedding, was associated with CRC risk.IMPACT: Further studies are needed to confirm our observed sex difference in the association and better explore the potential involvement of genetic variants of sRAGE in CRC development.

UR - http://www.scopus.com/inward/record.url?scp=85101026528&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-20-0855

DO - 10.1158/1055-9965.EPI-20-0855

M3 - Journal article

C2 - 33082206

VL - 30

SP - 182

EP - 192

JO - Cancer Epidemiology, Biomarkers & Prevention

JF - Cancer Epidemiology, Biomarkers & Prevention

SN - 1055-9965

IS - 1

ER -